New pill targets Hard-to-Treat cancers with RAS mutations
NCT ID NCT07252479
First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 18 times
Summary
This early-phase study tests a new daily pill, AN9025, in people with advanced solid tumors that have specific RAS gene mutations. The main goals are to check the drug's safety and find the right dose. About 91 adults will take the drug daily and visit the clinic regularly for monitoring.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS (PHASE 1) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITINGOrlando, Florida, 32827, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.